BridgeBio Pharma reported $36.7 million in US net revenue for its ATTR-CM treatment Attruby in the first full quarter since launch, with more than 2,000 prescriptions written by over 750 physicians as of late April. 

The company also posted rapid clinical progress across its late-stage rare disease programs and ended the first quarter of 2025 with $540.6 million in cash, bolstered by proceeds from a $500 million convertible notes offering.

Approved in the US in November 2024, acoramidis (marketed as Attruby) has seen strong early adoption, driven by what the company describes as significant clinical benefits – including a 42% reduction in all-cause mortality and recurrent hospitalizations, and a 50% reduction in cardiovascular hospitalizations over 30 months. Regulatory approvals for the drug (as Beyonttra) have since followed in the EU, UK, and Japan.

BridgeBio CEO Neil Kumar credited the early commercial success to Attruby’s efficacy and access strategy, and said: “This quarter’s announcements regarding our hypochondroplasia and hypoparathyroidism programs are good examples of our speed and breadth of capabilities.”

Among the most notable pipeline updates, the company completed enrollment significantly ahead of schedule in a run-in study for infigratinib in hypochondroplasia. The first patient has already been dosed in the Phase 2 interventional portion of the trial. The drug, an FGFR1-3 inhibitor, is also in a fully enrolled Phase 3 trial for achondroplasia, with top-line data expected in early 2026.

Encaleret, BridgeBio’s oral calcium-sensing receptor antagonist, delivered compelling Phase 2 proof-of-principle data in chronic hypoparathyroidism. In the small study (n=9), 78% of participants achieved normal blood and urine calcium levels within five days. BridgeBio plans to initiate a registrational trial in 2026. The drug is also being developed for autosomal dominant hypocalcemia type 1 (ADH1), with Phase 3 results expected in the second half of 2025.

BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) and BBP-812, a gene therapy for Canavan disease, also progressed. The company noted FDA alignment on an accelerated approval path for BBP-812 based on a surrogate biomarker.

BridgeBio’s first-quarter financials were reinforced by the successful pricing of $500 million in 1.75% convertible notes due 2031. Net proceeds of $563 million helped repay a term loan and repurchase shares. The company expects to receive an additional $105 million in milestone payments in the second quarter tied to Beyonttra’s approvals outside the US.